SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalNKTR Drug delivery Company


Previous 10 Next 10 
To: DewDiligence_on_SI who wrote (469)5/9/2019 3:19:23 PM
From: Miljenko Zuanic
   of 508
 
That trial, two centers (second is Anderson), was on my screen from day one. Inclusion/exclusion requirements are very strait (and demanding), with good response data and reasonable durability of response they may have path to accelerated approval. ASCO is not that far away.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (470)5/16/2019 9:58:28 AM
From: Miljenko Zuanic
   of 508
 
So much about accelerated approval,......... why they even mentioned at cc????

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (471)5/16/2019 12:08:15 PM
From: DewDiligence_on_SI
   of 508
 
Unless the sarcoma-IST data to be presented at ASCO are much, much better than the data in the ASCO abstract, I don't get why NKTR was touting this study on the recent CC.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: DewDiligence_on_SI who wrote (472)5/16/2019 1:37:45 PM
From: Miljenko Zuanic
   of 508
 
That was my point/concern. And Mary mentioned on cc, only FEW more subjects to be presented with data @ASCO????!!!!
<It is possible that Dr. Deangelo will be adding more patients to the roughly 50 that she included in her abstracts.>

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (473)5/30/2019 3:14:07 AM
From: Miljenko Zuanic
   of 508
 
Regorafenib for osteosarcoma:
ascopubs.org

Share RecommendKeepReplyMark as Last Read


From: Miljenko Zuanic6/1/2019 12:07:13 PM
   of 508
 
214 at ASCO-2019
nektar.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: Arthur Radley6/3/2019 7:44:30 AM
   of 508
 
Shares are up nearly $3.00 per share in pre-market, so Wall Street must like the new data.

Share RecommendKeepReplyMark as Last Read


To: Miljenko Zuanic who wrote (475)6/4/2019 1:19:17 AM
From: Miljenko Zuanic
   of 508
 
Enrolment rate and centers opening rate for melanoma P3 still *confuse* all what is done for 214, up to date. The only issue that I can think off is DRUG R&D supply SAMPLES, needed to conduce trial are IN SHORT???!!!

clinicaltrials.gov

Share RecommendKeepReplyMark as Last Read


From: Miljenko Zuanic6/13/2019 4:12:48 PM
   of 508
 
What was a base (May15 to May31) for +3M share short increase? What changed (negative) in business conduct/development????
Bit's me! Have no idea how other *stomachs* this kind on *nonsense* development????!!!

Share RecommendKeepReplyMark as Last Read


From: Miljenko Zuanic8/8/2019 8:02:35 PM
   of 508
 
MF Butcher Shop!

investors.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10